Showing 1 - 2 results of 2 for search 'M.S. Ernstoff', query time: 0.02s Refine Results
  1. 1
    Interim safety analysis of cancer immunotherapy trials Network – 12 (CITN-12): a Phase 1 study of pembrolizumab in patients with HIV and cancer

    Interim safety analysis of cancer immunotherapy trials Network – 12 (CITN-12): a Phase 1 study of pembrolizumab in patients with HIV and cancer by T.S. Uldrick, M.A. ‘Mac’ Cheever, P.H. Gonçalves, S. Fling, K. Aleman, B. Emu, M.S. Ernstoff, R. Gorelick, J. Kaiser, H. E Kohrt, A. Lacroix, M. Lindsley, L. M Lundgren, K. Lurain, F. Maldarelli, C. Parsons, E. Sharon, A. Widell, R. Yarchoan

    Published 2017-12-01
    Get full text
    Article
  2. 2
    Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

    Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group by I. Puzanov, A. Diab, K. Abdallah, C. O. Bingham, C. Brogdon, R. Dadu, L. Hamad, S. Kim, M. E. Lacouture, N. R. LeBoeuf, D. Lenihan, C. Onofrei, V. Shannon, R. Sharma, A. W. Silk, D. Skondra, M. E. Suarez-Almazor, Y. Wang, K. Wiley, H. L. Kaufman, M. S. Ernstoff, on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group

    Published 2017-11-01
    Get full text
    Article

Search Tools: